Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Witty Wishes Everyone Would Hold Off On GSK Break-Up Chatter

This article was originally published in Scrip

Executive Summary

There is an "extraordinarily low" likelihood of GlaxoSmithKline Plc. spinning off its consumer healthcare business within the next three years, said CEO Andrew Witty. Getting the margin structure right of the joint venture with Novartis was a "three year journey" and despite making "great progress" in 2015, there was still work to be done. "Time is everybody's friend here," said Witty, speaking during the presentation of GSK's annual results and fourth quarter financials on Feb. 3rd.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064388

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel